C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...

Hepatitis C, a bloodborne virus that damages the liver, can cause cirrhosis, liver cancer, liver failure and death if left ...

Atea Pharmaceuticals has announced the initiation of the Phase 3 C-FORWARD trial, which evaluates the combination regimen of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV). This trial ...

Taxpayers are covering rents of up to $3,879 per month in Colorado, leading taxpayer advocates to question the growing ...